AP NEWS
This content is a press release from our partner Business Wire. The AP newsroom and editorial departments were not involved in its creation.
PRESS RELEASE from provider: Business Wire
This content is a press release from our partner Business Wire. The AP newsroom and editorial departments were not involved in its creation.

Millendo Therapeutics, Inc. to Present at the Cowen and Company 39th Annual Healthcare Conference and the Oppenheimer 29th Annual Healthcare Conference

March 4, 2019

ANN ARBOR, Mich.--(BUSINESS WIRE)--Mar 4, 2019--Millendo Therapeutics, Inc. (Nasdaq: MLND), a clinical-stage biopharmaceutical company developing novel treatments for orphan endocrine diseases, announced today that Julia C. Owens, Ph.D., President and Chief Executive Officer, will present at two upcoming healthcare investor conferences.

Details on the Presentations:

Event: Cowen & Company 39 th Annual Health Care Conference
Date/Time: Monday, March 11, 2019 at 1:30 p.m. ET
Location: Boston, MA

Event: Oppenheimer 29 th Annual Healthcare Conference
Date/Time: Tuesday, March 19, 2019 at 3:55 p.m. ET
Location: New York, NY

Live webcasts of both presentations will be available on the Investors & Media section of Millendo’s website at http://investors.millendo.com. Replays of the webcasts will be archived on Millendo’s website for 30 days following the presentation.

About Millendo Therapeutics, Inc.
Millendo Therapeutics is a late-stage biopharmaceutical company focused on developing novel treatments for orphan endocrine diseases where current therapies do not exist or are insufficient. The Company’s objective is to build a leading endocrine company that creates distinct and transformative treatments for a wide range of endocrine diseases where there is a significant unmet medical need. The Company is currently advancing livoletide for the treatment of Prader-Willi syndrome and nevanimibe for the treatment of classic congenital adrenal hyperplasia and endogenous Cushing’s syndrome. For more information, please visit www.millendo.com.

View source version on businesswire.com:https://www.businesswire.com/news/home/20190304005147/en/

CONTACT: Millendo Investor Contact:

Stephanie Ascher

Stern Investor Relations

212-362-1200

stephanie@sternir.com

Millendo Media Contact:

Betsy Yates

MacDougall

781-235-3094

byates@macbiocom.com

KEYWORD: UNITED STATES NORTH AMERICA MASSACHUSETTS NEW YORK

INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY PHARMACEUTICAL

SOURCE: Millendo Therapeutics, Inc.

Copyright Business Wire 2019.

PUB: 03/04/2019 08:30 AM/DISC: 03/04/2019 08:30 AM

http://www.businesswire.com/news/home/20190304005147/en